-+ 0.00%
-+ 0.00%
-+ 0.00%

Karyopharm Therapeutics Affirms FY2026 Sales Guidance of $130.000M-$150.000M vs $133.736M Est

Benzinga·08/13/2026 11:32:17
Listen to the news
Karyopharm Therapeutics (NASDAQ:KPTI) affirms FY2026 sales outlook from $130.000 million-$150.000 million to $130.000 million-$150.000 million vs $133.736 million estimate.